Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 988 participants.
Also called NCT07405671
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 988 participants
- Registry
-
NCT07405671 -
2025-525121-13
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Belgium
- Registry status
- Recruiting
Technical summary
Registry record NCT07405671. Randomized; no masking; primary purpose treatment. Start 2026-09 (anticipated); primary completion 2029-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation
- Acronym
- ReCAST AF
- Condition
- Atrial Fibrillation (AF)
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- flecainide
- Intervention (Drug)
- Sotalol or Amiodarone
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Collaborator
- Research Foundation Flanders
Record details
- Record id
cardio:ct-nct07405671- Content hash
24fd0cf5757c5a3812b36e6992b6c9804ee1605066146dffe93faf64b695b7fd